Edgewise Therapeutics (EWTX)
(Delayed Data from NSDQ)
$17.66 USD
+0.05 (0.28%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $17.66 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Edgewise Therapeutics, Inc. (EWTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$32.50 | $48.00 | $25.00 | 84.55% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Edgewise Therapeutics, Inc. comes to $32.50. The forecasts range from a low of $25.00 to a high of $48.00. The average price target represents an increase of 84.55% from the last closing price of $17.61.
Analyst Price Targets (6 )
Broker Rating
Edgewise Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.17 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 83.33% and 16.67% of all recommendations. A month ago, Strong Buy made up 83.33%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/17/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
4/16/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
3/7/2024 | Piper Sandler | Yasmeen Rahimi | Not Available | Strong Buy |
9/17/2023 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.17 |
ABR (Last week) | 1.17 |
# of Recs in ABR | 6 |
Average Target Price | $32.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 85 of 252 |
Current Quarter EPS Est: | -0.36 |